There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling
The Paris Court of Appeals has handed down its judgment against Servier in the case involving its weight-loss therapy mediator, finding the company guilty of fraud and ord
A new non-invasive device from PureTech Health could help millions of overweight or obese people to slim down, allowing them to avoid surgery or prescription treatments.
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.